<?xml version="1.0" encoding="UTF-8"?>
<p id="p0040">Treatment with interferon Î² (IFNb)-1b (Bayer Pharmaceutical Co., Leverkusen, Germany), an immunomodulatory agent, was shown to result in clinical improvement among MERS-CoV-infected common marmosets, but the benefits of IFNb-1b for SARS patients remains uncertain.
 <xref rid="bib29" ref-type="bibr">
  <sup>29</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib30" ref-type="bibr">
  <sup>30</sup>
 </xref>
</p>
